Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

f completion of enrolment for the Phase II AGW trial of Topical Interferon Alpha-2b; the timing of a future Phase I/II clinical study for L-DOS47 in Poland; sufficiency of the Company's cash reserves and expected cash flow from operations; and other information in future periods, which statements and information can be identified by the use of forward-looking terminology such as "plans", "expected", "intends"; "estimates", "next", "anticipated", "developing", "will" or variations thereon, or comparable terminology referring to future events or results. Although Helix believes that the expectations reflected in such forward-looking statements and information are reasonable, such statements and information involve risks and uncertainties, and undue reliance should not be placed on such statements and information. Certain material factors or assumptions are applied in making forward-looking statements and providing forward-looking information, including, but not limited to, patient recruitment rates and the timely and successful completion of ongoing clinical trials, GMP manufacturing and other activities; the timely provision of services by third parties; future revenue, costs and regulatory approvals. Important factors that could cause actual results to differ materially from these forward-looking statements and information include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all and which if not obtained will have a material adverse impact on the Company and its ability to continue, or if not obtained in a timely manner, may result in the Company's having to discontinue or delay one or more of its product development programs or other initiatives; uncertainty whether Topical Interferon Alpha-2b or L-DOS47 will be successfully developed and commercialized as a drug or at all; the risk that the FDA is not bound by its pre-IND meetings; uncertainty whether any of the timelines mentione
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... PHIA) and Volcano Corporation (NASDAQ: VOLC ), a ... applications, today announced that they have entered into a definitive ... tender offer to acquire all of the issued and outstanding ... total equity purchase price of USD 1 billion (approx. EUR ...
(Date:12/17/2014)... HOLBROOK, N.Y. , Dec. 17, 2014 /PRNewswire/ ... that The Depository Trust Company (DTC) has made ... the Deposit Chill on the Company,s stock effective ... of Northstar,s common stock for depository and book ... and the Company is now once again fully ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Jan. 22 Protalix,BioTherapeutics, Inc. (Amex: PLX ... concept results in an animal study conducted as ... is being conducted under the agreement the Company ... the technology transfer,arm of the Hebrew University of ...
... approved to reduce both A1C and LDL cholesterol, ... Inc.,announced that the United States Food and Drug ... glycemic control,(measured as hemoglobin A1C) in adults with ... or insulin, either alone or in,combination with other ...
Cached Medicine Technology:Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 2Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 3Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 2Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 3Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 4Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 5Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 6Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 7
(Date:12/21/2014)... AZ (PRWEB) December 21, 2014 Parker ... range of heating, cooling, plumbing and other similar home ... in 2014 with regard to its expert contracting services. ... industry leader that has been serving Arizona for well ... in providing the absolute best in quality customer service ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 SCI ... of the issues and systemic barriers for disabled athletes ... Paratriathlon Champion. Scheidies has a condition called juvenile macular ... He describes how he adapted his athletic ambitions to ... his success in triathlon to pioneer the way for ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... blood clots from using testosterone products such as AndroGel ... that the male hormone testosterone may increase the risk ... in the Proceedings of the National Academy of Sciences ... of male rats with naturally occurring colon cancer. Dr. ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted their ... offices. The Hope for the Holidays Toy Drive is a ... families during the holiday season. This year, the toy drive ... both offices. This event continues to be successful year after ... store managers and assistant managers came out and not only ...
(Date:12/20/2014)... 2014 BambooIndustry.com is a professional company ... The business has recently shown its new engineered bamboo ... its bamboo flooring models. , BambooIndustry.com’s customers come from ... and more. According to the CEO of the company, ... fast in the past few years, and the demand ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2
... CHERRY HILL, N.J., Aug. 25 Nuvilex, Inc. (OTC Bulletin ... on September 1, 2009. Additionally, regional shareholder meetings will be held ... and Los Angeles on September 18th. Regional shareholder meeting times and ... , "We are very aware of our shareholders, ...
... , , , IRVINE, ... the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion ... by U.S. News & World Report as one of ,America,s ... SET pulse oximetry technology. , , ...
... DALLAS Aug. 25, 2009 Minorities have poorer results ... used to remove plaque from inside the carotid artery, according ... author of the study in the journal Stroke. ... July issue of the journal, found that higher rates of ...
... T. Chu, MD, PhD, associate professor at the University ... professor, Massachusetts Institute of Technology, received the 2009 Julie ... The Ellison Medical Foundation, the grants provide funding of ... in advancing understanding of basic aging and its impact ...
... , , ... Iowa has agreed to pay the United States $4.5 million to resolve ... announced today. , , ... claims to Medicare by having financial relationships with five physicians that violated ...
... ... MyClyns Product, the New Personal Germ Protection Spray , ... Mount Kisco, NY (PRWEB) August 25, 2009 -- ... media agency specializing in national brand OTC health and beauty products, recently signed an ...
Cached Medicine News:Health News:Nuvilex to Issue Positive Shareholder Newsletter 2Health News:Nuvilex to Issue Positive Shareholder Newsletter 3Health News:Nuvilex to Issue Positive Shareholder Newsletter 4Health News:Nuvilex to Issue Positive Shareholder Newsletter 5Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 2Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 3Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 4Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 5Health News:Minorities have poorer results, higher rates of inappropriate surgery to prevent stroke 2Health News:Ellison Medical Foundation awards more than $1 million to mid-career scientists 2Health News:Covenant Medical Center to Pay U.S. $4.5 Million to Resolve False Claims Act Allegations 2Health News:Robin Leedy & Associates Wins Social Media Program For Union Springs Pharmaceuticals 2
The 40D is ideal for pediatric ophthalmoscopy and other examinations requiring expansive fundus visibility. Alternatively, this lens may be used at the slit lamp biomicroscope to provide an extremely...
This excellent mid-power lens provides medium field and magnification, with an ideal diameter for grip andmanipulation in the orbital area....
The 15D provides high magnification along with an optimized working distance from the cornea. With its 4.11x magnification it is also well suited for disc and macular observation....
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
Medicine Products: